Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Summary

The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg with lanreotide 40mg PR in subjects with active acromegaly.

Timeline

Start

2014-10

Primary completion

2016-11

Completion

2017-02-16

Outcome

Met primary endpoint

paper Lanreotide autogel was non-inferior to lanreotide 40 mg PR: treatment difference (95% CI) for IGF-1 SDS between groups was - 0.32 (- 0.74, 0.11; per protocol population) PMID 32366244 ↗

paper CONCLUSIONS: Lanreotide autogel was non-inferior to lanreotide 40 mg PR in Chinese patients with active acromegaly after 32 weeks of treatment. PMID 32366244 ↗

Publications

• An Z, Lei T, Duan L, Hu P, Gou Z, Zhang L, Durand-Gasselin L, Wang N, Wang Y, Gu F; LANTERN study investigators. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). BMC Endocr Disord. 2020 May 4;20(1):57. doi: 10.1186/s12902-020-0524-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanreotide	Other / unclassified	40 mg	Subcutaneous
Subject	Lanreotide	Other / unclassified	60 mg	Subcutaneous
Subject	Lanreotide	Other / unclassified	90 mg	Subcutaneous
Subject	Lanreotide	Other / unclassified	120 mg	Subcutaneous

Indications